A decision from an opposition division of the European Patent Office may have “far-reaching consequences” for US patent holders, Solveig Moré tells LSIPR.
At the European Patent Office (EPO), GlaxoSmithKline (GSK) challenged a patent owned by US research group the Institute for Systems Biology (ISB), on numerous grounds of opposition including lack of novelty and inventive step.
ISB’s application for a European patent (EP) is directed to the medical use of a peptide that induces an immune response and is based on an international patent application claiming priority of a US patent application filed in 2001.
Until recently, the US Patent and Trademark Office required that all patent applications name the inventor as the applicant, whereas international applications claiming US priority will often name a company, usually the inventor’s employer, as the applicant.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
EPO, GlaxoSmithKline, Institute for Systems Biology, EP, entitlement to priority